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Objective: to determine the ability of participants in the Burden of Obstructive Lung Disease
(BOLD) study to meet quality goals for spirometry test session quality and to assess factors
contributing to good quality.
Methods: Following 2 days of centralized training, spirometry was performed pre- and post-
bronchodilator (BD) at 14 international sites, in random population-based samples of persons
aged 40 years, following a standardized protocol. The quality of each test session was eval-
uated by the spirometer software and an expert reading center. Descriptive statistics were
calculated for key maneuver acceptability variables. A logistic regression model identified
the predictors of acceptable quality test sessions.
Results: About 96% of test sessions met our quality goals for a low back-extrapolated volume
(BEV), time to peak flow (PEFT), and end-of-test volume (EOTV). The mean forced expiratory
time (FET) was 10.4 s. Ninety percent of the maneuvers with the highest FVC had a forced expi-
ratory time (FET) > 6.8 s. About 90% of test sessions had FEV1 and FVC which were repeatable
within 150 mL. Test quality was slightly better for post-BD test sessions when compared to pre-
BD. Independent predictors of adequate test quality included female sex, younger age, higher
education, lack of dyspnea, higher pre-BD FEV1, less BD responsiveness, and study site.2 4482 3300; fax: þ43 662 4482 3303.
at (B. Lamprecht).
1 Elsevier Ltd. All rights reserved.
1508 P. Enright et al.Conclusions: Quality goals for spirometry tests were met about 90% of the time in these
population-based samples of adults from several countries.
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The airway obstruction of COPD is determined by a low
post-bronchodilator (post-BD) FEV1/FVC and the severity
of the airway obstruction is determined by the FEV1
(percent predicted). Poor quality spirometry tests can
cause either a falsely high or a falsely low FEV1/FVC (false
negative or false positive interpretation of airway
obstruction) and an under-reported FEV1 (more severe
airway obstruction).
The current ATS/ERS goals for acceptable and repeat-
able spirometry tests1 are based on the ability of well-
trained technologists to meet these goals in 9 of every 10
adult patients referred for testing in a single hospital-based
pulmonary function laboratory in the United States.2
Spirometry quality has been reported from a large study
of workers participating in the World Trade Center
Responders program in New York City.3 However, very little
has been published about the ability of population-based
samples of adults from many countries to meet these
goals for spirometry done post-bronchodilator (as for COPD
case-finding). The storage of the spirometry results from
the BOLD study provided this opportunity.Methods
The design of BOLD is described in detail elsewhere4 and only
summarizedhere.A list ofall participatingentities in theBOLD
Collaborative Research Group is included as an Addendum.
Participating sites were expected to recruit a population-
based sample of at least 600 non-institutionalized adults
(300 women and 300 men), ages 40 and older, living in a well-
defined administrative area (the “target population”) whose
total population exceeded 150,000. In this paper we report
data from the first 14 BOLD sites. A more detailed description
of these sites appears elsewhere.5
For this paper, data are limited to individuals with
questionnaire data and both pre- and post-bronchodilator
spirometry. The BOLD questionnaires included information
on respiratory symptoms, risk factors for COPD, co-
morbidities, and respiratory diagnoses, and were adminis-
tered in face-to-face interviews by trained and certified
staff. Each site obtained approval from their local ethical
committee and written informed consent from each
participant.
The same model of spirometer was purchased for each
site. The spirometer model (ndd EasyOne Diagnostic model
2001, Zurich, Switzerland) was chosen to minimize the risk
of cross-contamination, for portability, to provide auto-
mated quality checks and messages, and to store the results
for transfer to a personal computer database. Spirometer
calibration checks were done using a 3.00 L calibration
syringe at a single speed every day of testing and once
a month at 3 speeds (to check linearity), per ATS/ERSguidelines.1 This spirometer has been demonstrated to
remain accurate for prolonged periods of time.6 Spirometry
was performed before and 15 min after the administration
(using a spacer) of 200 mg of albuterol/salbutamol.
At least one team member from each site was centrally
trained for two days at the beginning of the program by
a pulmonary specialist with considerable experience in
spirometry testing. These technologists were qualified
clinical technologists (at least 3 years training), nurses, or
fieldworkers with no prior experience with spirometry.
Spirometry was performed either in the homes of partici-
pants or at a local healthcare center. The participants were
vigorously coached by the technicians to perform up to 8
FVC maneuvers until a quality grade of A or B was displayed
on the spirometer. (See the Appendix for EasyOne quality
grade details.) Results from the best 3 maneuvers (highest
sum of FEV1 plus FVC) were stored by the spirometer.
Adequate quality was considered a grade of A, B, or C.
The quality of all test sessions was reviewed by the BOLD
Pulmonary Function Reading Center (RJ). Quality reports
were regularly sent to the BOLD clinical centers, as done in
the Lung Health Study.7 If the overall quality for the most
recent 10 tests was considered sub-optimal, the site prin-
cipal investigator was required to provide remedial
spirometry training for the technologist(s) who were per-
forming inadequately. It was recommended that the tech-
nician not perform additional testing for the study until
retraining and recertification was completed.
To assess the overall quality of performance by our
subjects and technicians for this paper, descriptive statis-
tics were calculated for the maneuver acceptability vari-
ables BEV and PEFT from the maneuver with the highest
FEV1; EOTV and FET from the maneuver with the highest
FVC; and for FVC and FEV1 repeatability (dFVC and dFEV1,
highest minus second highest).8
To identify significant influences on performance,
a logistic regression analysis was performed with adequate
quality as the dependent variable. The initial regressions
included age (in ten year increments), sex, smoking status
(current or former smoker versus never smoker), education
level (9 or more years of school), dyspnea (MRC grade 2 or
higher), pre-BD FEV1 (%predicted), BD responsiveness (%
change from baseline), and study site. A p-value <0.02 was
considered significant.
Airway obstruction was defined as FEV1/FVC below the
fifth percentile lower limit of the normal range (LLN)9 and
FEV1 below 65% predicted, using NHANES III reference
equations for Caucasians10 (regardless of reported race or
ethnicity). Spirometric restriction was defined as FVC below
the LLN with FEV1/FVC above the LLN.
Results
About half of the study participants were men; one-fourth
were current smokers; one-third were former smokers;
Table 1 Characteristics and spirometry results from the 9893 participants (including those with poor quality spirometry tests):
mean, 5th, and 95th percentiles.
Mean 5th 95th
Age, yrs 56.5 41 78
Height, cm 166 150 184
Weight, Kg 75.1 50 105
BMI 27.1 19.8 36.7
Pre-BD Post-BD
Mean 5th 95th Mean 5th 95th
FEV1, L 2.66 1.27 4.19 2.74 1.37 4.30
FEV1, % pred 88.6% 54.6 116.5 91.4% 59.2 18.9
FVC, L 3.60 1.93 5.56 3.60 1.97 5.54
FVC, % pred 92.8% 64.0 119.8 92.9% 65.8 119.9
FEV1/FVC 0.74 0.57 0.85 0.76 0.59 0.87
Quality of spirometry in the BOLD study 1509one-fourth were obese (BMI >30); 7.1% reported current
asthma; 11% reported MRC grade 2e5 dyspnea; 4.8% had
airway obstruction; 20.4% had spirometric restriction, and
the mean BD response was a 3.7% higher FEV1 (SD 7.1%).
Table 1 presents additional characteristics of the partici-
pants and descriptive statistics for the key spirometry
variables. Overall, 96% of pre-bronchodilator test sessions
and 97% of post-bronchodilator test sessions had adequate
quality (EasyOne quality grades A, B, or C), although this
varied amongst BOLD sites from a low of 86% to a high of
100% (Table 2).
The highest FEV1 and the highest FVC are used to obtain
the FEV1/FVC which is used to determine airway obstruc-
tion, so the quality of these maneuvers is important. The
accuracy of the FEV1 in this ratio depends on a maximally
deep breath and then a small BEV and PEFT. Table 3 shows
that the BEV was below 154e158 mL in 90% of the maneu-
vers with the highest FEV1; and the PEFT was less than
110 ms in 90% of these maneuvers. The accuracy of the FVC
depends on a maximally deep breath and then a long
maneuver with a small end-of-test volume, indicating a flat
volume-time plateau. The FETwas more than 6.4 s in 90% of
the maneuvers with the highest FVC; and the EOTV was
smaller than 26e30 mL in 90% of these maneuvers.Table 2 Success rates for obtaining adequate quality (ndd
EasyOne grade A, B, or C) by BOLD study site.
Site Tests Pre-BD Post-BD
Sydney, Australia 585 88.3% 88.6%
Salzburg, Austria 1347 98.1% 97.3%
Vancouver, Canada 856 99.0% 98.3%
Guangzhou, China 590 97.7% 97.1%
Hannover, Germany 711 99.4% 98.3%
Reykjavik, Iceland 759 100% 100%
Lexington, Kentucky 559 86.4% 94.1%
Bergen, Norway 707 90.2% 93.6%
Manila, Philippines 918 99.8% 99.1%
Krakow, Poland 601 92.0% 95.5%
Cape Town, South Africa 896 95.6% 96.5%
Uppsala, Sweden 587 94.0% 94.3%
Adana, Turkey 864 98.6% 98.0%
London, U.K. 691 99.6% 97.8%Unless the technologist is watching the subject during
spirometry, the depth of the inhalation which preceded the
forced exhalation can only be estimated by the repeat-
ability of the FEV1 and FVC (the highest value minus the
second highest value). In 90% of the test sessions, the FEV1s
matched within 129e138 mL and the FVCs matched within
149e163 mL (pre- and post-BD respectively) (Table 3).
The ATS/ERS 2005 goals for spirometry quality for adults
were set so that 90% of the patients seen in the pulmonary
function laboratory of a large clinic could meet each of
them.11 Table 4 shows that each of the maneuver accept-
ability goals were also met in the single best maneuver by
about 90% or more of the participants of the BOLD study. As
expected, the study participants were slightly more
successful during post-BD test sessions when compared to
pre-BD test sessions (when they were test naı¨ve). The ATS/
ERS FEV1 and FVC repeatability goal is <150 mL. BOLD
participants met these goals in 92.4% and 87.4% of pre-BD
test sessions (dFEV1 and dFVC, respectively) and 93.5 and
90.3% of post-BD test sessions (dFEV1 and dFVC
respectively).
For the purpose of detecting “slow starts,” addition of
the PEFT threshold of >120 ms added very little to use of
the traditional BEV threshold of >150 mL (Fig. 1). The BEV
quality check was significantly more likely (p < 0.001) than
PEFT to flag maneuvers as having a slow start (11e12%
versus 7e8% failure rate, respectively). Only 5e6% of
maneuvers with an acceptable BEV had an unacceptable
PEFT. Maneuvers with a slow start (PEFT >120 ms) were
significantly more likely (p < 0.001) to be stopped before
6 s (perhaps because the technologist quickly recognized
the body language of the slow start and stopped the
maneuver prematurely to re-instruct the participant).
Short maneuvers (FET < 6.0 s) in these adults were
significantly more likely (p < 0.001) to lack have a flat
volume-time plateau, as measured by an EOTV <40 mL
(Fig. 2). About 39% of pre-BD maneuvers which lasted less
than 4 s (and 15% of those with FET between 4 and 6 s) had
a high EOTV, compared to just 3% for maneuvers lasting at
least 6 s. Comparable post-BD figures were 23%, 9%, and
2.4%. In participants with clinically important airway
obstruction post-BD, shorter maneuvers within a test
session were significantly (p < 0.001) associated with
smaller FVCs (Fig. 3).
Table 3 Results of quality checks from 9893 test sessions.
Pre-BD Post-BD
Mean 5th 90th 95th Mean 5th 90th 95th
BEV, mL 99 36 158 185 98 39 154 178
PEFT, ms 85 60 110 120 84 60 110 120
FET, sec 10.1 5.3 6.5a 9.6 5.4 6.4a
EOTV, mL 16 5 30 38 15 5 26 34
dFEV1, mL 65 4 138 172 61 4 129 164
dFVC, mL 80 6 163 194 74 4 149 184
BEV and PEFT are from the maneuver with the highest FEV1.
FET and EOTV are from the maneuver with the highest FVC.
a A short FET is not desirable, so the 10th percentile for FET is given instead of the 90th percentile.
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1510 P. Enright et al.Independent predictors of success in meeting quality
goals for post-BD test sessions (EasyOne quality grade A, B,
or C) included female sex, younger age, higher education,
less dyspnea, a lower pre-BD FEV1, less BD responsiveness,
and study site (Table 5). However, these factors explained
only about 10% of the overall variability in quality. Smoking
status, MRC grade 1 dyspnea, and asthma were not signifi-
cant independent predictors of spirometry quality. We did
observe a significant ageesex interaction, but we removed
this term from the final model to make the coefficients
easier to understand. The odds ratios for acceptable quality
from each of the other 13 sites (when compared to the
Sydney, Australia site) ranged from 2.1 to 13.3 with all p-
values 0.003.
Discussion
Despite a diversity of settings, languages, and ethnicities,
these population-based samples of adults and the tech-
nologists who tested them achieved as high success rates in
meeting spirometry quality goals as did patients seen in the
PFT lab of a major referral medical center in the US (Mayo
Clinic in Minnesota).2,12 The thresholds specified by ATS/
ERS 2005 standards1 were set near the 90th percentile, so
that about 10% of patients (both children and adults) fail to
meet each criterion when tested by an experienced tech-
nician using a diagnostic quality spirometry system.2
Some individual BOLD sites were more likely to produce
FVC maneuvers with short exhalation times (data not
shown), which likely underestimated the prevalence of
airway obstruction at that site. Submaximal inhalationsTable 4 “Best maneuver” acceptability rates (per ATS/
ERS 2005).
pre-BD post-BD
BEV <150 mL 88.1% 89.1%
PEFT <120 ms 91.8% 93.2%
FET >6sec 92.4% 92.6%
EOTV <40 mL 95.6% 96.9%
BEV and PEFT are from the maneuver with the highest FEV1.
FET and EOTV are from the maneuver with the highest FVC.cause under-estimates of the FVC and FEV1. Poor blast
efforts can cause under-estimates of the FEV1,
13 while
short exhalation times cause under-estimates of the FVC
and the FEV1/FVC.
The spirometry maneuver may be divided into 3 steps (or
phases), each of which requires a different type of effort: 1)
“take adeepbreath” (maximal inhalation), 2) “blast out your
air” (maximal exhalation effort), and 3) “keep blowing until
all your air is gone” (prolonged exhalation). Poor effort may
occur during any (or all) of these steps, and is usually due to
sub-optimal interaction between the technologist and the
subject. A submaximal inhalation falsely reduces all of the
results (except for the ratios). A submaximal blast during the
second phase reduces themeasured PEF, variably affects the
FEV1, and may increase the FVC.
14 A premature termination
of the exhalation falsely reduces the FVC (and the FEV6, if it
occurs before 6 s), and is detected by a high end-of-test
volume (EOTV).0
<50 [50,100) [100,150) [150,200) [200,250) >=250
Figure 1 Box and whisker plots show the relationship
between back-extrapolated volume (BEV in mL) and time to
peak flow (PEFT in msec) for detecting slow starts in post-BD
test sessions. BEV was categorized in 50 mL increments. A
BEV >150 mL or a PEFT >120 ms indicates an unacceptably
slow start. The bottom and top of each box indicate the 25th
and 75th percentiles, while the bottom and top whiskers indi-
cate the 5th and 95th percentiles. Only 19% of the variation in
BEV was explained by the variation in PEFT.
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Figure 2 Box and whisker plots show the relationship
between the end-of-test volume (EOTV in mL) and the forced
expiratory time (FET) for detecting premature terminations of
FVC maneuvers. ATS/ERS acceptability thresholds are <45 mL
for EOTV and >6.0 s for FET. The bottom and top of each box
indicate the 25th and 75th percentiles, while the bottom and
top whiskers indicate the 5th and 95th percentiles. Note that
after 6 s, fewer than 5% of maneuvers had an unacceptable
EOTV (corresponding to a flat plateau on the volume-time
curve).
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the above faults, and thereby to identify any poorly per-
formed maneuver or test session which could result in false
positive or false negative diagnoses in the clinical setting,
or increased measurement noise/bias in epidemiologic and
intervention studies. Poor inhalation effort is common, but
is not objectively evident in any single spirometric record.0
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Figure 3 The relationship between shorter forced expiratory
times and smaller FVCs within post-BD test sessions in the
subset of 559 adults with clinically important airway obstruc-
tion (FEV1/FVC below the lower limit of the normal range and
FEV1 below 65% predicted). Within each test session, the
maneuver with the highest FVC was considered the best FVCb,
which was then compared to the maneuver with the shortest
FET (FVCs). dFVC (in milliliters on the vertical axis) Z FVCb
minus FVCs. About 37% of the differences in FVC were
explained by shorter FETs. Similar relationships were seen pre-
BD and in all study participants (but with lower R-squared
values, data not shown).Thus poor inhalation effort can be detected only in terms of
poorly reproducible FVC and FEV1 across multiple maneu-
vers. Submaximal blast and premature termination can,
however, be identified objectively from the recording of
any single blow.
The second phase of the spirometry maneuver is to
BLAST out the air as quickly as possible, thereby achieving
a “sharp” (high) peak flow during the first tenth of a second
and a high average flow during the first second of the
maneuver (FEV1). A hesitating start creates a high back-
extrapolated volume (BEV), causing an error in the
measured FEV1, so the ATS guidelines consider maneuvers
with a high BEV to be unacceptable. A long time to reach
peak flow (PEFT) indicates a relatively slow start, or lack of
a maximal effort to blast out the air.
The ATS/ERS goal for a rapid start-of-test (BEV < 0.15 L,
whichever is greater) wasmet inmore than 90% of tests done.
The software version of EasyOne used for this project (version
2.10) had a low pass filter designed to remove high frequency
flow “noise” above 10 Hz. This filter reduced the PEFT and
PEF (FEFmax) somewhat for very sharp blast efforts.
End-of-test maneuver acceptability criteria are designed
to detect maneuvers which “quit too soon” resulting in an
under-estimation of the true FVC. The ATS/ERS 2005
recommendations require FET >6 s for adults, and an
“obvious plateau” in the volume-time curve. About 90% of
the post-BD maneuvers with the highest FVC in our study
achieved an EOTV of less than 29 mL.
The correlates of good quality spirometry have also been
reported for other studies of adults.2,3,12,15,16 The indi-
vidual technologists performing the tests are the most
common source of variability in quality. In the BOLD study,
these technologist differences are represented by the study
sites, since we did not ask technologists within each site to
identify themselves for each test. Participant characteris-
tics, such as female sex, younger age (within adulthood),
and higher education which independently predict success
in meeting quality goals are consistent between these
studies and the BOLD study. Those with respiratory symp-
toms, airway obstruction, or bronchodilator responsiveness
were slightly less likely to meet quality goals, especially for
a flat volume-time curve (small EOTV). The lack of an
independent association with a history of asthma with poor
quality suggests that maneuver-induced bronchospasm is
rare in adults with asthma.
This study adds unique information when compared to
previous studies of spirometry quality.17e22 Many countries
were included in the BOLD study, making the results broadly
generalizable, while other studies were performed in only
one city or one country. This study used a modern flow-
sensing spirometer with automated quality checks and
messages (in contrast to some previous studies which used
volumespirometerswhichmake it easier tomeetEOTVgoals,
since the exhaled air is cooling and contracting inside the
spirometer during the final seconds of each maneuver). The
most recent ATS/ERS goals for spirometry quality1 were used
by the BOLD study; and both pre- and post-BD test results
were analyzed, making the results more applicable for COPD
case-finding, which uses post-BD spirometry results.
Our results confirm and expand the results of previous
studies of spirometry quality. A large study from Bergen
Norway included only men ages 30e46 (younger than the
Table 5 Summary of logistic regression modela for predicting adequate post-bronchodilator spirometry.
Variable Odds Ratio (multivariate) 95% CI p-value Odds Ratio (univariate) 95% CI p-value
Female gender 1.89 (1.49, 2.40) <0.001 1.61 (1.29, 2.01) <0.001
Age (increase of 10 years) 0.83 (0.75, 0.92) <0.0001 0.70 (0.64, 0.77) <0.001
Current vs. never smoking 1.20 (0.87, 1.65) 0.26 1.27 (0.96, 1.70) 0.095
Ex vs. never smoking 1.29 (0.99, 1.69) 0.058 1.05 (0.82, 1.35) 0.68
MRC dyspnea level 1 vs. level 0 0.99 (0.68, 1.44) 0.94 1.01 (0.71, 1.45) 0.95
MRC dyspnea levels 2e3 vs.
level 0
0.55 (0.35, 0.86) 0.008 0.67 (0.44, 1.00) 0.052
MRC dyspnea levels 4e5 vs.
level 0
0.45 (0.28, 0.72) 0.001 0.50 (0.34, 0.76) 0.001
Unable to walkb vs. level 0 0.60 (0.42, 0.85) 0.005 0.50 (0.37, 0.68) <0.001
Education grade 9e12 vs. 0e8 1.54 (1.14, 2.07) 0.004 1.28 (0.99, 1.64) 0.055
Education grade 13 þ vs. 0e8 1.66 (1.16, 2.37) 0.005 1.67 (1.26, 2.22) <0.001
Bronchodilator response
(increase of 1% point)
0.96 (0.94, 0.97) <0.0001 0.97 (0.95, 0.98) <0.001
Pre-BD FEV1, % (increase of 10%
points)
0.88 (0.82, 0.94) <0.0001 0.97 (0.92, 1.03) 0.34
a indicators of site (p < 0.001) were also included in the model though not shown in table.
b unable to walk for reasons other than lung disease.
1512 P. Enright et al.age for which COPD case-finding is indicated) and only pre-
BD spirometry.18 About 90% of the almost 30,000 men in
that study met the 1993 European goals for FEV1 and FVC
repeatability (<5% or <100 mL), which is the same rate as
for BOLD participants meeting current repeatability goals.
A more recent study from Bergen, Norway performed both
pre- and post-BD spirometry for men and women around
ages 47 and 72.22 As in the BOLD study (which included 707
men and women from Bergen, Norway), male gender, older
age, and dyspnea were independent predictors of poor
quality post-BD spirometry. As in our study, they found
slightly better quality post-BD when compared to pre-BD.
They found that obesity and cognitive impairment (in the
older study participants) were also associated with poorer
quality, but we did not measure these factors. Our protocol
suggested stopping after 8 maneuvers, but one-third of
their participants were coached to perform more than 8
maneuvers, which was successful for obtaining good quality
98% of the time.
A 1992 study of spirometry quality in young adults (ages
20e45) working in Montreal offices found that 89% met the
goal of FEV1 repeatability within 100 mL.
19 Currently
smoking women, men with a history of asthma or eczema,
and men or women with positive methacholine challenge
results were more likely to have poorer FEV1 repeatability.
In the six U.S. cities study of 8522 white adults, 91% met the
goal of FEV1 repeatability within 5% or 100 mL.
20 Dyspnea
and a history of asthma were independent predictors of
poorer quality. While we did not perform inhalation chal-
lenge tests, we found that BD responsiveness (which is
associated with asthma and bronchial responsiveness) was
an independent predictor of poorer quality spirometry.
Limitations of this study
The EasyOne spirometer did not label maneuvers with FET
<6sec or EOTV >40 mL as unacceptable. Our criterion for
acceptable quality (A, B, or C quality grade from theEasyOne spirometer) included test sessions which did not
meet ATS/ERS 2005 goals for quality, which require FEV1
and FVC repeatability within 150 mL (equivalent to an
EasyOne quality grade A). Our results may not apply to
subjects under age 40. Measurements of PEFT and EOTV
may differ when using other models of spirometers. Some
of the relationships will vary when only patients with severe
obstruction or restriction are studied. Quality was probably
enhanced by careful training before the field work began,
followed by monthly feedback from the Reading Center.
The Reading Center reviews found maneuver errors (such as
zero flow errors and the lack of a volume-time plateau)
which were reported back to the study sites but not
reflected in the ndd quality grades which were analyzed for
this manuscript.
Summary
We found that 90% or more of our participants were
successfully coached to perform pre-BD forced expiratory
spirometric maneuvers which met acceptability criteria for
BEV, EOTV, FET; and within-test session maneuver repeat-
ability for FEV1 and FVC. Participant characteristics can
influence performance; but their overall effect is small
with well-trained technicians who have experience.Appendix: EasyOne diagnostic spirometer
model maneuver quality checks (firmware
version 2.10)
The message “Don’t hesitate” was displayed when the BEV
was higher than 150 mL (or 5%, whichever was greater). If
the time to peak flow (PEFT) was <120 ms, the message was
“Blast out faster.” The maneuver was marked as unac-
ceptable by the spirometer if either of these thresholds
were exceeded.
Quality of spirometry in the BOLD study 1513If the end-of-test volume (EOTV) was above 45 mL during
the final 2 s, or when the BEV was >100 mL during the final
0.5 s when the forced expiratory time (FET) was less than
6 s for an adult, the message “Blow out longer” was dis-
played. These criteria were not used by the spirometer to
determine acceptability.
Test Session Quality Grades: The quality of each
spirometry test session was graded as follows (displayed
after each maneuver and printed on the report):
A Z 3 þ acceptable maneuvers, AND FEV1 and FVC
match within 150 mL.
B Z 3 þ acceptable maneuvers, AND FEV1 and FVC
match within 200 mL.
C Z 2 þ acceptable maneuvers, AND FEV1 and FVC
match within 250 mL.
D Z Only 1 acceptable maneuver, OR the FEV1 or the
FVC from the best 2 acceptable maneuvers do not match
within 250 mL.
F Z No acceptable maneuvers.
The message “Session Complete! Good Job” was dis-
played with a grade of A or B after 3 or 4 maneuvers, or C or
better after 5 or more maneuvers.
Footnote: Some of these quality criteria were changed
for EasyOne spirometers manufactured after September
2007 (with firmware versions 2.17 and higher).Abbreviations
ATS American Thoracic Society
BEV back-extrapolated volume
BMI body mass index
dFEV1 the difference between the highest and
second highest FEV1 within a spirometry test
session
EOTV end-of-test volume (mL exhaled during the
final 2.0 s)
FET forced expiratory time
PEF peak expiratory flow (as determined by
spirometry)
PEFT peak expiratory flow time (the time in
milliseconds from back-extrapolated time
zero until the peak flow occurs)
QA Quality assuranceAddendum
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Jiachun Lu, Pixin Ran, Dali Wang, Jingping Zheng, Yumin
Zhou (Guangzhou Institute of Respiratory Diseases,
Guangzhou Medical College, Guangzhou, China); Ali
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(Cukurova University School of Medicine, Department of
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University, Department of Pulmonary Medicine, Salz-
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Tina Endresen, Lene Svendsen (Department of Thoracic
Medicine, Institute of Medicine, University of Bergen,
Bergen, Norway); Wan C. Tan (PI), Wen Wang (iCapture
Center for Cardiovascular and Pulmonary Research,
University of British Columbia, Vancouver, BC, Canada);
David M. Mannino (PI), John Cain, Rebecca Copeland, Dana
Hazen, Jennifer Methvin, (University of Kentucky, Lex-
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